New antiplatelet agents for cardiovascular disease
نویسندگان
چکیده
منابع مشابه
Antiplatelet therapy in cardiovascular disease.
Platelet activation and aggregation are considered to be central to arterial thrombus formation. Antiplatelet therapy is therefore important for both the treatment and prevention of cardiovascular disease. Aspirin, the most widely used antiplatelet agent, inhibits platelet cyclo-oxygenase and the conversion of arachidonic acid to the potent platelet agonist thromboxane A(2) but does not prevent...
متن کاملNew antiplatelet agents and prosthetic heart valves.
Sir, Despite advances in prosthetic valve design, patients who undergo valve replacement are at risk of arterial thromboembolism and valve thrombosis. We present four cases where new antiplatelet agents have been used. A 61-year-old man with aortic valve endocarditis underwent early mechanical valve replacement. He developed mitral regurgitation and an aorticright-atrial fistula requiring surgi...
متن کاملNew anticoagulants in combination with antiplatelet agents.
The use of new, direct anticoagulants is increasing. Data from both controlled trials and clinical practice have shown that these drugs are as efficacious and safe as warfarin for deep vein thrombosis and pulmonary embolism, and as stroke prophylaxis for patients with atrial fibrillation. But what if platelet inhibition is also indicated? In the following, the combination of antiplatelets and t...
متن کاملAntiplatelet Agents, Anticoagulants: New Medical Strategies
The pathogenesis of stroke Stroke is a heterogeneous condition in which 85% is caused by arterial acute occlusion or ischaemic stroke and 15% blood vessel rupture or cerebral haemorrhage. Of those with ischaemic stroke, further heterogeneity is evident with cerebral ischaemia caused by artery-to-artery emboli, in situ small vessel disease or cardiac emboli. The underlying pathogenesis can usual...
متن کاملOral antiplatelet agents and chronic kidney disease.
C hronic kidney disease (CKD) is recognized as an independent predictor for myocardial infarction, stroke and all-cause mortality due to accelerated atherosclerosis. Cardiovascular mortality accounts for 45% of allcause mortality in CKD patients, while in end-stage renal disease (ESRD) death attributable to arrhythmic mechanisms is responsible for 27% of the cardiovascular mortality observed in...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Canadian Medical Association Journal
سال: 2013
ISSN: 0820-3946,1488-2329
DOI: 10.1503/cmaj.130033